Company profile for Protagonist Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities (NCEs) that can potentially transform existing treatment paradigms in disease areas with significant unmet medical needs. We have successfully utilized the platform to date to identify oral, GI-restricted peptides (PTG-100 and PTG-200) for inflammatory bowel diseases (IBD) ...
a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities (NCEs) that can potentially transform existing treatment paradigms in disease areas with significant unmet medical needs. We have successfully utilized the platform to date to identify oral, GI-restricted peptides (PTG-100 and PTG-200) for inflammatory bowel diseases (IBD) and injectable peptides (PTG-300) for rare blood disorders.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
7707 Gateway Boulevard, Suite 140 Newark, CA 94560-1160 USA
Telephone
Telephone
+1 510 474 0170
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20251205962286/en/Protagonist-and-Takeda-Present-Longer-Term-Data-at-ASH-2025-Showing-Rusfertide-Delivers-Durable-Response-and-Hematocrit-Control-in-Polycythemia-Vera

BUSINESSWIRE
06 Dec 2025

https://www.pharmiweb.com/press-release/2025-11-06/protagonist-reports-third-quarter-2025-financial-results-and-provides-corporate-update

PHARMIWEB
06 Nov 2025

https://www.pharmiweb.com/press-release/2025-11-03/protagonist-therapeutics-announces-oral-and-poster-presentations-on-rusfertide-at-the-67th-annual-as

PHARMIWEB
03 Nov 2025

https://www.pharmiweb.com/press-release/2025-10-27/protagonist-announces-new-icotrokinra-data-in-ulcerative-colitis-and-plaque-psoriasis-presented-at-t

PHARMIWEB
27 Oct 2025

https://www.prnewswire.com/news-releases/icotrokinra-maintains-standout-combination-of-therapeutic-benefit-and-a-favorable-safety-profile-in-once-daily-pill-through-28-weeks-in-ulcerative-colitis-302594371.html

PR NEWSWIRE
27 Oct 2025

https://www.fiercebiotech.com/biotech/jj-talks-pen-new-chapter-protagonist-partnership-buyout-wsj

FIERCE BIOTECH
11 Oct 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty